Molecular Research on Human Immunodeficiency Virus (HIV)

Dear Colleagues,

It has been four decades since HIV/AIDS was first clinically detected in 1981 in the United States. Despite effective antiretroviral medication and advanced schedules and regimens, lack of an effective vaccine makes HIV/AIDS still a major public health problem globally. Our progress in understanding human diseases and molecular biology in general have substantially improved due to many extraordinary discoveries and numerous studies on retroviruses. Research on HIV-1 has largely contributed to our current understanding of human retrovirus biology. HIV-1 constitutes the major for of the infection and is considered to the primary driver of the pandemic while HIV-2 is responsible for a smaller subgroup of infections. Significant genetic, morphological, and physiologic differences have been identified between HIV-1, HIV-2, and HTLV-1. Many of the research into HIV-1 infection have been influenced by HTLV-1, which was the first human retrovirus to be discovered. Existing research has demonstrated that retroviruses differ significantly one another and each one should be studied separately to understand the differences in biology including cellular and molecular mechanisms of replication and mutagenesis. In this special issue, we invite researchers to submit original and review articles on key differences between these viruses with respect to molecular mechanisms, diversification, and their potential effect on pathogenicity. In addition, we would also consider topics such as HIV-1, HIV-2, and HTLV-1 gene expression and regulation, genetic diversity, and molecular determinants of mutagenesis.

Dr. Muni Rubens
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• core gene
• glycoprotein
• reverse transcription
• integration
• genetic diversity
• Apolipoprotein B Editing Complex (APOBEC3) proteins
• Adenosine Deaminase RNA Specific (ADAR) proteins